Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04668209 · ClinicalTrials.gov registry record · Phase 2
Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)
A Phase 2 study, sponsored by University of Arizona.
- Terminated
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT04668209 is a Phase 2 study that was terminated before completion, run by University of Arizona. The registered enrollment target is 31 participants.
The verdict
NCT04668209, a Phase 2 study, was terminated before completion, sponsored by University of Arizona.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This multi-center, open-label, 2 arm parallel-group, randomized, interventional prospective exploratory study in 40 patients aimed to evaluate safety and explore putative clinical benefits of Silmitasertib 1000 mg BID dose in patients with severe illness caused be SARS-COV-2. This will be a two-arm trial comparing the SOC/best supportive care alone to the SOC/best supportive care with addition of Silmitasertib (allocation ratio 1:1).
Interventions
- DRUG Silmitasertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2021-01-21 |
| Est. Completion | 2022-10-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04668209
The ClinicalTrials.gov registry entry for NCT04668209 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Silmitasertib is the first listed.
NCT04668209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04668209 about?
NCT04668209 is a clinical study titled "Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)". This multi-center, open-label, 2 arm parallel-group, randomized, interventional prospective exploratory study in 40 patients aimed to evaluate safety and explore putative clinical benefits of Silmitasertib 1000 mg BID dose in patients with severe illness caused be SARS-COV-2. This will be a two-arm ...
What is the current status of trial NCT04668209?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2021-01-21. Estimated completion is 2022-10-19.
What interventions are being tested in trial NCT04668209?
The interventions under investigation include: Silmitasertib (DRUG).
Who is sponsoring clinical trial NCT04668209?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.